Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Печать: 2151-8017
ISSN Онлайн: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015013982
pages 145-194

From Targets to Targeted Therapies in Hepatocellular Carcinoma

Melchiorre Cervello
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR) Palermo, Italy
Maria Rita Emma
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
Giuseppa Augello
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy; Biomedical Department of internal Medicine and Specialties, University of Palermo, Via del Vespro 143, 90127
Daniele Balasus
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
Antonina Azzolina
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
James A. McCubrey
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA
Antonella Cusimano
Institute of Biomedicine and Molecular Immunology "Alberto Monroy", National Research Council (CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy

Краткое описание

Prognosis in advanced hepatocellular carcinoma (HCC) remains poor, despite the great improvement in the knowledge of the mechanisms behind hepatocarcinogenesis in recent years. Therapeutic options in the advanced stage of disease were quite limited until the introduction of sorafenib, a multi-kinase inhibitor. Sorafenib is considered the first systemic therapy and the only approved drug in advanced HCC. Unfortunately, sorafenib efficacy is rather limited in terms of overall survival, especially compared to results obtained with targeted therapies in other solid tumors; this limited efficacy is probably related to the heterogeneity of HCC. Consequently, a molecular characterization of HCC is urgently needed to improve treatments for and the clinical outcomes of HCC patients. This review offers a summary of the major studies regarding the signaling pathways involved in HCC pathogenesis, and an overview of the most promising drug treatments, apart from sorafenib, and the potential for their application in new therapeutic interventions in HCC.